コンテンツへスキップ
Merck

Actual treatment of overactive bladder and urge urinary incontinence.

Minerva urologica e nefrologica = The Italian journal of urology and nephrology (2013-03-30)
J N Cornu
要旨

Overactive bladder (OAB) is defined by its hallmark symptom, urgency. It can be associated with urge urinary incontinence (UUI), and dramatically impact the patients' quality of life. Etiologies of OAB are numerous, and under this common wording, virtually all the population is covered (men as well as women, patients with or without neurogenic disease, and all age categories). OAB and UUI management have been historically based on non-interventional therapies, antimuscarinics, and surgery. In the last decade, innovations in the treatment of this highly prevalent condition have been multiple, and further insights came from various horizons (drug invention, innovative use of existing drugs, new medical devices, tissue engineering, gene and cell therapy). Notably, the use of BoNT and neuromodulation techniques have deeply modified the algorithm of specialized OAB management, delaying surgery indications and offering mini-invasive alternatives to patient refractory to behavioral and medical treatment. Whilst some of these techniques are about to reach maturity, numerous questions remain unsolved about their indications, long term effects, rank in the armamentarium, cost-effectiveness, hypothetical combination or sequential use. The present review depicts the actual wide range of options available for OAB management in adults, focusing on the latest evolutions. When relevant, a distinction was made between genders and OAB subtypes (idiopathic vs neurogenic) regarding treatment outcomes.

材料
製品番号
ブランド
製品内容

Supelco
カフェイン, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
カフェイン, powder, ReagentPlus®
Sigma-Aldrich
カフェイン, anhydrous, 99%, FCC, FG
Supelco
融点スタンダード235~237°C, analytical standard
Supelco
カフェイン, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
カフェイン 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
カフェイン, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
カフェイン, Sigma Reference Standard, vial of 250 mg
Sigma-Aldrich
カフェイン, meets USP testing specifications, anhydrous
Supelco
カフェイン 溶液, analytical standard, 1.0 mg/mL in methanol
Supelco
Mettler-Toledo®キャリブレーション用物質ME 18872、カフェイン, traceable to primary standards (LGC)
Sigma-Aldrich
カフェイン, anhydrous, tested according to Ph. Eur.
Sigma-Aldrich
カフェイン, BioXtra
システム適合性用カフェイン, European Pharmacopoeia (EP) Reference Standard
カフェイン, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
カフェイン, SAJ special grade, ≥98.5%